Table 2 Response rates for patients without cirrhosis
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Genotype | Treatment | Duration (weeks) | SVR (%) | Trials |
|---|---|---|---|---|
1 | Telaprevir + Peginterferon-alpha + Ribavirin | 12 + 12 or 12 + 36 | 75 | ADVANCE |
Harvoni | 12 | 98 | ION | |
Olysio + Sovaldi | 12 | 95 | COSMOS | |
Viekira Pak + Ribavirin | 12 | 96 | SAPPHIRE | |
Sofosbuvir + Peginterferon + Ribavirin | 12 | 92 | NEUTRINO | |
2 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 81 | FISSION |
Sofosbuvir + Ribavirin (Treatment-naïve) | 12 | 97 | FISSION | |
Sofosbuvir + Ribavirin (Non-responders & Relapsers) | 12 | 90 | FUSION | |
16 | 92 | FUSION | ||
3 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 81 | FISSION |
Sofosbuvir + Ribavirin (Treatment-naïve) | 24 | 93 | VALENCE | |
Sofosbuvir + Ribavirin (Non-responders & Relapsers) | 12 | 37 | FUSION | |
16 | 63 | FUSION |